| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
In a study of the 2018, E3C1 in Del1 was found to affect the change of cell membrane properties in vitro. In a 2019 study, treated by cisplatin (CDDP) + E3C1 inhibited tumor growth in explanted tumor in nude mice. Furthermore, treated by CDDP + E3C1 improved the life prognosis of mice. In a 2020 Study revealed that the therapeutic effect of CDDP+E3C1 is a change in the number and morphology of tumor blood vessels. These results suggest that gene therapy with CDDP+E3C1 for mouse transplanted tumors affects the properties of endothelial cells of tumor blood vessels and cell membranes of cancer cells. As a result, it was thought that the growth of mouse explanted tumors was inhibited. Furthermore, it was suggested that the prognosis of mice was prolonged.
|
